Nav: Home

Bile duct cancer study sheds light on triggers that cause disease

October 10, 2016

Scientists have identified a molecule that drives the development of bile duct cancer.

The research in mice sheds new light on what triggers the disease and how the illness progresses.

Experts say that further research will be needed but the findings could eventually reveal opportunities to improve diagnosis and develop new therapies.

Researchers at the University of Edinburgh focused on a family of molecules called Notch, which are critical for the formation of bile ducts as the liver develops in an embryo.

The team looked at whether these molecules are involved in bile duct cancer and found that one of them - Notch 3 - is a key driver of tumour development.

Mice that do not have the Notch 3 gene develop fewer tumours and those that do form are much smaller in size, the study found.

The researchers showed that Notch 3 triggers a pathway of signalling molecules called AKT, which drives cells in the tumour to reproduce uncontrollably.

Tissue samples from patients with bile duct cancer had higher levels of Notch 3 than samples from normal liver, suggesting that blocking the molecule could offer a new way of treating the disease in people.

The researchers caution that much more research is needed before a therapy could be developed but the findings could help to improve diagnosis.

Bile ducts are found in the liver and are important for helping to drain toxins. Cancer of the bile ducts - known as cholangiocarcinoma - is the second most common primary liver cancer and has a very poor prognosis.

The disease is difficult detect and often isn't accurately diagnosed until the tumour is too advanced for surgery, which is the only curative treatment. Other treatment options are limited as the cancer typically does not respond well to chemotherapy.

Cases of bile duct cancer have risen steeply and steadily across the world over the past decades. In 2013, more than 2000 people died from the disease in England alone and fewer than one in 20 patients will survive for five years after diagnosis.

The study, published in the Proceedings of the National Academy of Sciences, was funded by Wellcome, the Medical Research Council, AMMF - the Cholangiocarcinoma Charity, Cancer Research UK and the European Research Council.

Professor Stuart Forbes, of the MRC Centre for Regenerative Medicine at the University of Edinburgh, said: "Identifying the signals that drive bile duct cancer growth gives us hope of finding new ways of tackling the disease. We next need to assess how Notch 3 could be targeted with drugs so that we can investigate whether this approach offers the potential for a new therapy."

Miss Rachel Guest, a Clinical Lecturer in General Surgery at the University of Edinburgh, said: "It is crucial that we find methods to diagnose bile duct cancer earlier and this molecule may be one opportunity to do this. Although more studies are needed before this becomes a reality, cholangiocarcinoma has previously been under-researched and this work is a welcome insight into a very deadly cancer."

Helen Morement, Chief Executive Officer of AMMF - The Cholangiocarcinoma Charity, commented: "The Notch 3 findings by the Edinburgh team are potentially very important. Cholangiocarcinoma is a truly devastating disease, with very little in the treatment armoury - to have discovered an area that may lead to a novel therapy is certainly welcomed by AMMF."
-end-


University of Edinburgh

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Jumpstarting Creativity
Our greatest breakthroughs and triumphs have one thing in common: creativity. But how do you ignite it? And how do you rekindle it? This hour, TED speakers explore ideas on jumpstarting creativity. Guests include economist Tim Harford, producer Helen Marriage, artificial intelligence researcher Steve Engels, and behavioral scientist Marily Oppezzo.
Now Playing: Science for the People

#524 The Human Network
What does a network of humans look like and how does it work? How does information spread? How do decisions and opinions spread? What gets distorted as it moves through the network and why? This week we dig into the ins and outs of human networks with Matthew Jackson, Professor of Economics at Stanford University and author of the book "The Human Network: How Your Social Position Determines Your Power, Beliefs, and Behaviours".